| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer
DOI: 10.1016/j.critrevonc.2012.01.002
Abstract: Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that...
|
Miguel A. Climent,
Josep Mª Piulats,
Alfredo Sánchez-Hernández,
José Ángel Arranz,
Javier Cassinello,
Jesús García-Donas,
Aránzazu González del Alba,
Luis León-Mateos,
Begoña Mellado,
Mª José Méndez-Vidal,
Begoña Pérez-Valderrama
et al.
|
Review article
(In Press Corrected Proof)
|
30 January 2012 |
|
Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges
DOI: 10.1016/j.critrevonc.2011.09.004
Abstract: Non-small cell lung cancer is the leading cause of cancer death in the United States. Efforts to improve outcomes have led to a greater understanding of the predictive and prognostic value o...
|
Corey J. Langer
|
Review article
(In Press Corrected Proof)
|
27 January 2012 |
|
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
DOI: 10.1016/j.critrevonc.2012.01.001
Abstract: The impact of age as a poor prognostic factor in chronic myeloid leukemia (CML) has been well described. In the interferon era, elderly patients diagnosed as having chronic phase chronic mye...
|
Massimo Breccia,
Mario Tiribelli,
Giuliana Alimena
|
Review article
(In Press Corrected Proof)
|
27 January 2012 |
|
Octreotide for malignant bowel obstruction: Twenty years after
DOI: 10.1016/j.critrevonc.2011.12.006
Highlights: ► We presented the original idea regarding the rationale of using octrotide in maligant bowel obstruction. ► We presented the subsequent literature supporting the efficacy of octreotide. ►...
|
Sebastiano Mercadante,
Giampiero Porzio
|
Review article
(In Press Corrected Proof)
|
25 January 2012 |
|
Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?
DOI: 10.1016/j.critrevonc.2011.12.008
Highlights: ► DWI shows potential for response prediction and monitoring. ► Some studies show that low pretreatment ADC is related to response to therapy. ► An increase in ADC during/after treatment i...
|
Linda Heijmen,
Maartje C.H.M. Verstappen,
Edwin E.G.W. ter Voert,
Cornelis J.A. Punt,
Wim J.G. Oyen,
Lioe-Fee de Geus-Oei,
John J. Hermans,
Arend Heerschap,
Hanneke W.M. van Laarhoven
et al.
|
Review article
(In Press Corrected Proof)
|
24 January 2012 |
|
Malnutrition in childhood cancer patients: A review on its prevalence and possible causes
DOI: 10.1016/j.critrevonc.2011.12.003
Abstract: Purpose: To perform a systematic literature review for critical evaluation of prevalence and factors contributing to malnutrition in childhood cancer. Methods: A systematic search resulting ...
|
Aeltsje Brinksma,
Gea Huizinga,
Esther Sulkers,
Willem Kamps,
Petrie Roodbol,
Wim Tissing
et al.
|
Review article
(In Press Corrected Proof)
|
24 January 2012 |
|
Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review
DOI: 10.1016/j.critrevonc.2011.11.009
Highlights: ► We present an overview of Stereotactic Body Radiation Therapy for prostate cancer, followed by a critical evaluation of the current literature. ► We highlight the unique suitability of p...
|
Stefano Arcangeli,
Marta Scorsetti,
Filippo Alongi
|
Review article
(In Press Corrected Proof)
|
19 January 2012 |
|
Target therapy in elderly breast cancer patients
DOI: 10.1016/j.critrevonc.2011.12.004
Abstract: Substantial progress has been made in the management of breast cancer by targeting HER2 and VEGF pathways. Although the efficacy and safety of target therapy in breast cancer have been estab...
|
Paolo Carli,
Elisa Turchet,
Daniela Quitadamo,
Antonella Spada,
Gianmaria Miolo,
Elda Lamaj,
Simon Spazzapan,
Vincenzo Di Lauro,
Riccardo Dolcetti,
Andrea Veronesi,
Diana Crivellari
et al.
|
Review article
(In Press Corrected Proof)
|
19 January 2012 |
|
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
DOI: 10.1016/j.critrevonc.2011.11.010
Highlights: ► The development of reversible EGFR inhibitors was a critical step in NSCLC therapy. ► Recently, irreversible and/or multitargeted inhibitors have also been evaluated. ►Clinical trials wi...
|
Sai-Hong Ignatius Ou
|
Review article
(In Press Corrected Proof)
|
18 January 2012 |
|
PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis
DOI: 10.1016/j.critrevonc.2011.10.002
Highlights: ► FDG-PET/CT is a valid instrument for the detection of recurrent or metastatic gynaecologic tumours. ► Evidence corroborates FDG-PET/CT's role in ovarian cancer in monitoring response to ...
|
Maurizia Dalla Palma,
Michele Gregianin,
Pasquale Fiduccia,
Laura Evangelista,
Anna Rita Cervino,
Giorgio Saladini,
Lucia Borgato,
Maria Ornella Nicoletto,
Vittorina Zagonel
et al.
|
Review article
(In Press Corrected Proof)
|
16 January 2012 |
|
Targeted therapies in the treatment of germ cell tumors: The need for new approaches against “orphan” tumors
DOI: 10.1016/j.critrevonc.2011.12.001
Highlights: ► GCTs are generally highly sensitive to cisplatin-based chemotherapy and represent a model for curable neoplasms. ► Between 15%–20% of patients with metastatic disease still progress and ...
|
Alfonso Sánchez-Muñoz,
Begoña Jiménez-Rodríguez,
Víctor Navarro-Pérez,
Laura Medina-Rodríguez,
Casilda Llácer,
Luis Vicioso,
Javier Machuca,
Emilio Alba
et al.
|
Review article
(In Press Corrected Proof)
|
10 January 2012 |
|
Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models
DOI: 10.1016/j.critrevonc.2011.11.008
Highlights: ► Selection of patients for phase I clinical trials remains a critical issue. ► There is no reliable and validated guidance to estimate life-expectancy. ► Numerous scores and models for pr...
|
Anne Ploquin,
David Olmos,
Charles Ferté,
Philippe A. Cassier,
Andrew Kramar,
Alain Duhamel,
Nicolas Penel
et al.
|
Review article
(In Press Corrected Proof)
|
09 January 2012 |
|
Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models
DOI: 10.1016/j.critrevonc.2011.11.007
Highlights: ► Liver cancers cause significant mortality worldwide. ► Experimental models show that liver cancers are characterized by epithelial-mesenchymal transition (EMT). ► EMT-related markers may...
|
Olorunseun O. Ogunwobi,
Chen Liu
|
Review article
(In Press Corrected Proof)
|
19 December 2011 |
|
Mechanobiology of tumor invasion: Engineering meets oncology
DOI: 10.1016/j.critrevonc.2011.11.005
Highlights: ► Tumor invasion, the process by which cells physically dissociate from primary tumors, is a rate-limiting step in metastasis. ► Invasion depends on coordination of intracellular molecular...
|
Shawn P. Carey,
Timothy M. D’Alfonso,
Sandra J. Shin,
Cynthia A. Reinhart-King
|
Review article
(In Press Corrected Proof)
|
19 December 2011 |
|
Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia
DOI: 10.1016/j.critrevonc.2011.11.006
Highlights: ► We review and discuss the role of IL-12, IL-23 and IL-27 in pediatric B-ALL. ► The cytokines show direct anti-leukemic activity with similar and different mechanisms. ► IL-27 is able to ...
|
Claudia Cocco,
Vito Pistoia,
Irma Airoldi
|
Full-length article
(In Press Corrected Proof)
|
16 December 2011 |
|
How to select the optimal therapy for early-stage prostate cancer
DOI: 10.1016/j.critrevonc.2011.11.001
Abstract: Selecting the “optimal therapy” for the patient with localized prostate cancer may be one of the most challenging medical decisions facing the oncologist. Most patients will have a number of...
|
Marisa A. Kollmeier,
Michael J. Zelefsky
|
Review article
(In Press Corrected Proof)
|
09 December 2011 |
|
Not all sarcomas developed in irradiated tissue are necessarily radiation-induced – Spectrum of disease and treatment characteristics
DOI: 10.1016/j.critrevonc.2011.11.004
Abstract: Background: Sarcomas in irradiated tissue (SITs) are often considered with second cancers, although they usually present distinct dose–response, genetic and clinical patterns. The contributi...
|
Juliette Thariat,
Antoine Italiano,
Fabrice Collin,
Antoine Iannessi,
Pierre-Yves Marcy,
Alexis Lacout,
Isabelle Birtwisle-Peyrottes,
Antoine Thyss,
Jean-Léon Lagrange
et al.
|
Review article
(In Press Corrected Proof)
|
06 December 2011 |
|
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy
DOI: 10.1016/j.critrevonc.2011.10.008
Abstract: The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function. Treatment options for intermediate- and advanced-stage disease are limited. Transcathet...
|
Riccardo Lencioni
|
Review article
(In Press Corrected Proof)
|
06 December 2011 |
|
Missing: A diagnostic technique to enumerate antigen-specific T cells
DOI: 10.1016/j.critrevonc.2011.11.002
Abstract: T lymphocytes are responsible for immune responses against pathogens, immune surveillance against cancer and maintenance of tolerance to self. While techniques available to detect antigen-sp...
|
Melinda Shelley Suchard
|
Review article
(In Press Corrected Proof)
|
05 December 2011 |
|
Oral health status in children with acute lymphoblastic leukemia
DOI: 10.1016/j.critrevonc.2011.11.003
Abstract: Leukemia is a malignancy of the bone marrow. Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and accounts for nearly 75% of all newly diagnosed leukemias and 25% o...
|
Fawad Javed,
Achint Utreja,
Fernanda O. Bello Correa,
Mansour Al-Askar,
Malik Hudieb,
Faisal Qayyum,
Abdulaziz Al-Rasheed,
Khalid Almas,
Khalid Al-Hezaimi
et al.
|
Review article
(In Press Corrected Proof)
|
05 December 2011 |
|
Integration of cell biology, pharmacological modeling and statistical analysis: Part I: Cell biology and PK/PD in the Oncology paradigm
DOI: 10.1016/j.critrevonc.2011.10.004
Abstract: The motivation of this two-part review article is to provide a comprehensive picture of cancer, cancer drugs and the detection and treatment of cancer. In order to do so, this article integr...
|
Revathi Ananthakrishnan,
Sandeep Menon
|
Review article
(In Press Corrected Proof)
|
28 November 2011 |
|
Polycomb genes and cancer: Time for clinical application?
DOI: 10.1016/j.critrevonc.2011.10.007
Abstract: Polycomb group genes (PcGs) are epigenetic effectors, essential for stem cell self-renewal and pluripotency. Two main Polycomb repressive complexes (PRC1, PRC2) mediate gene silencing throug...
|
Francesco Crea,
Elisa Paolicchi,
Victor E. Marquez,
Romano Danesi
|
Review article
(In Press Corrected Proof)
|
23 November 2011 |
|
New perspectives in the treatment of metastatic renal cell carcinoma
DOI: 10.1016/j.critrevonc.2011.10.005
Abstract: Since 2007, the advent of so-called “targeted” therapy has revolutionized the management of renal cell carcinoma (RCC), replacing interferon or interleukin-2 immunotherapy. The present artic...
|
Jérôme Barrière,
Benjamin Hoch,
Jean-Marc Ferrero
|
Review article
(In Press Corrected Proof)
|
18 November 2011 |
|
Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat
DOI: 10.1016/j.critrevonc.2011.10.006
Abstract: Sustaining hemostasis in clinical hemorrhages is a challenging task and requires extensive effort to stabilize medically hard-to-treat traumatic injuries. Several hemostatic agents are prefe...
|
Berat Z. Haznedaroglu,
Yavuz Beyazit,
Sharon L. Walker,
Ibrahim C. Haznedaroglu
|
Review article
(In Press Corrected Proof)
|
14 November 2011 |
|
Secondary malignancies in survivors of breast cancer: How to overcome the risk
DOI: 10.1016/j.critrevonc.2010.06.007
Abstract: Secondary radiation-induced cancers (SRIC) are rare but well-documented as long-term side effects of radiation in a large population of breast cancer survivors. The estimate of the standardi...
|
Mark Shilkrut,
Yazid Belkacemi,
Abraham Kuten,
on behalf of AROME
|
Review article
(In Press Corrected Proof)
|
07 November 2011 |
|
Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence
DOI: 10.1016/j.critrevonc.2011.09.009
Abstract: The increasing use of FDG-PET (18F-2-fluoro-2-deoxy-d-glucose positron emission tomography) imaging in the staging of non-small-cell lung cancer (NSCLC) may result in a significant shift in ...
|
S. Novello,
M. Giaj Levra,
T. Vavalà
|
Review article
(In Press Corrected Proof)
|
07 November 2011 |
|
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
DOI: 10.1016/j.critrevonc.2011.09.006
Abstract: In the last fifty years the combining of different drugs has progressively improved response and survival rates in gynaecological malignancies. Results are, however, far from being satisfact...
|
Filippo Bellati,
Chiara Napoletano,
Maria Luisa Gasparri,
Ilary Ruscito,
Claudia Marchetti,
Sandro Pignata,
Federica Tomao,
Pierluigi Benedetti Panici,
Marianna Nuti
et al.
|
Review article
(In Press Corrected Proof)
|
07 November 2011 |
|
Hepatosplenic gamma-delta T-cell lymphoma
DOI: 10.1016/j.critrevonc.2011.10.001
Abstract: Hepatosplenic T-cell lymphoma (HSTL) is a rare and aggressive extranodal lymphoma derived mostly from cytotoxic γδ T-cells. The peak incidence is in adolescents and young adults, and is more...
|
Andrés J.M. Ferreri,
Silvia Govi,
Stefano A. Pileri
|
Review article
(In Press Corrected Proof)
|
02 November 2011 |
|
Defining and predicting indolent and low risk prostate cancer
DOI: 10.1016/j.critrevonc.2011.10.003
Abstract: The early detection of asymptomatic prostate cancer has led to the increased incidence of tumours that are unlikely to become symptomatic during life, so called indolent cancers. The predict...
|
Chris H. Bangma,
Monique J. Roobol
|
Review article
(In Press Corrected Proof)
|
28 October 2011 |
|
Adjuvant early breast cancer systemic therapies according to daily used technologies
DOI: 10.1016/j.critrevonc.2011.09.002
Highlights: ► Various adjuvant breast cancer guidelines are available. ► These consensual statements can be optimized using locally available daily used technologies. ► The conjunction of the Adjuvant...
|
W. Jacot,
M. Gutowski,
D. Azria,
G. Romieu
|
Review article
(In Press Corrected Proof)
|
24 October 2011 |
|
Cancer prevalence and mortality in centenarians: A systematic review
DOI: 10.1016/j.critrevonc.2011.09.007
Abstract: Life expectancy has dramatically expanded, the global population has aged unprecedentedly and the number of centenarians has significantly increased. The analysis of autopsy series, cancer r...
|
Nicholas Pavlidis,
Giorgio Stanta,
Riccardo A. Audisio
|
Review article
(In Press Corrected Proof)
|
24 October 2011 |
|
The intersection between cannabis and cancer in the United States
DOI: 10.1016/j.critrevonc.2011.09.008
Abstract: In the last 15years there has been a major shift in the laws governing medical use of cannabis in the United States. Corresponding with this change there has been escalating interest in the ...
|
Daniel W. Bowles,
Cindy L. O’Bryant,
D. Ross Camidge,
Antonio Jimeno
|
Review article
(In Press Corrected Proof)
|
24 October 2011 |
|
Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva
DOI: 10.1016/j.critrevonc.2011.09.003
Abstract: Several clinical–pathological parameters have been related to survival of patients with invasive squamous cell carcinoma of the vulva, whereas few studies have investigated the ability of bi...
|
Angiolo Gadducci,
Roberta Tana,
Cecilia Barsotti,
Maria Elena Guerrieri,
Andrea Riccardo Genazzani
et al.
|
Review article
(In Press Corrected Proof)
|
20 October 2011 |
|
Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations
DOI: 10.1016/j.critrevonc.2011.09.001
Highlights: ► Duration of cognitive impairment varied across different generations of chemotherapy regimens. ► Concurrent administration of multiple cytotoxic agents could lead to a synergistic declin...
|
Yin Ting Cheung,
Wai Keung Chui,
Alexandre Chan
|
Review article
(In Press Corrected Proof)
|
20 October 2011 |
|
The case for wider use of recombinant factor VIII concentrates
DOI: 10.1016/j.critrevonc.2011.08.001
Abstract: The introduction of clotting factor concentrates led to major advances in hemophilia care. Rather than simply providing an alternative to plasma-derived concentrates, the introduction in the...
|
Cedric Hermans,
Hans-Hermann Brackmann,
Piercarla Schinco,
Günter Auerswald
|
Review article
(In Press Corrected Proof)
|
03 October 2011 |
|
Necroptosis: An emerging form of programmed cell death
DOI: 10.1016/j.critrevonc.2011.08.004
Highlights: ► Necroptosis is one particular form of programmed necrosis induced by stimulating death receptors with agonists. ► Necroptosis has its own unique signaling pathway which requires the invo...
|
Wei Wu,
Peng Liu,
Jianyong Li
|
Review article
(In Press Corrected Proof)
|
03 October 2011 |
|
Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
DOI: 10.1016/j.critrevonc.2011.08.005
Abstract: Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal u...
|
Sergio Bracarda,
Enzo Maria Ruggeri,
Marcello Monti,
Marco Merlano,
Alessandro D’Angelo,
Francesco Ferraù,
Enrico Cortesi,
Armando Santoro
et al.
|
Review article
(In Press Corrected Proof)
|
26 September 2011 |
|
Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy
DOI: 10.1016/j.critrevonc.2011.08.006
Abstract: Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastati...
|
Santiago Aparo,
Sanjay Goel
|
Review article
(In Press Corrected Proof)
|
26 September 2011 |
|
Second-line therapy for refractory renal-cell carcinoma
DOI: 10.1016/j.critrevonc.2011.08.008
Abstract: In the last 5 years inhibitors of the VEGF/VEGFR and mTOR pathways have dramatically changed the therapeutic approach to metastatic renal cancer. Randomized controlled trials have shown that...
|
Fable Zustovich,
Giuseppe Lombardi,
Ornella Nicoletto,
Davide Pastorelli
|
Review article
(In Press Corrected Proof)
|
23 September 2011 |
|
May intra-operative radiotherapy have a role in the treatment of prostate cancer?
DOI: 10.1016/j.critrevonc.2011.08.007
Abstract: Treatment of locally advanced prostate cancer is still a challenge. Combined treatments including hormone therapy, radiotherapy, and/or surgery can achieve less than 50% of disease free surv...
|
Marco Krengli,
Carlo Terrone,
Barbara Alicja Jereczek-Fossa,
Debora Beldì,
Roberto Orecchia
et al.
|
Review article
(In Press Corrected Proof)
|
19 September 2011 |
|
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
DOI: 10.1016/j.critrevonc.2011.04.012
Highlights: ► We revise the current knowledge in chemotherapy-induced peripheral neurotoxicity. ► Several effective antineoplastic drugs are harmful to peripheral nerves. ► Incidence of the damage is ...
|
Andreas A. Argyriou,
Jordi Bruna,
Paola Marmiroli,
Guido Cavaletti
|
Review article
(In Press Corrected Proof)
|
12 September 2011 |
|
Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions
DOI: 10.1016/j.critrevonc.2011.08.003
Abstract: Systemic chemotherapy (CT) with platinum-based doublets result in modest improvements in both overall survival (OS) and quality of life in good performance status patients with advanced non-...
|
Ana Custodio,
Javier de Castro
|
Review article
(In Press Corrected Proof)
|
12 September 2011 |
|
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions
DOI: 10.1016/j.critrevonc.2011.08.002
Abstract: Nilotinib is a second generation ABL tyrosine kinase inhibitor (TKI) that exerts major anti-leukemic effects in newly diagnosed patients with chronic myeloid leukemia (CML) as well as in mos...
|
Peter Valent,
Günther Gastl,
Klaus Geissler,
Richard Greil,
Oliver Hantschel,
Alois Lang,
Werner Linkesch,
Thomas Lion,
Andreas L. Petzer,
Elisabeth Pittermann,
Lisa Pleyer,
Josef Thaler,
Dominik Wolf
et al.
|
Review article
(In Press Corrected Proof)
|
07 September 2011 |
|
Osteosarcomas of the mandible: Are they different from other tumor sites?
DOI: 10.1016/j.critrevonc.2011.07.001
Abstract: Background: Osteosarcomas of the mandible (MOS) affect 1/10millionpersons/year, mostly the young adult. Due to lack of specific data, the treatment of MOS is extrapolated from that of extrag...
|
Juliette Thariat,
Morbize Julieron,
Anne Brouchet,
Antoine Italiano,
Thomas Schouman,
Pierre-Yves Marcy,
Guillaume Odin,
Alexis Lacout,
Olivier Dassonville,
Isabelle Peyrottes-Birstwisles,
Robert Miller,
Antoine Thyss,
Nicolas Isambert
et al.
|
Review article
(In Press Corrected Proof)
|
25 August 2011 |
|
Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead
DOI: 10.1016/j.critrevonc.2011.06.005
Highlights: ► Rhabdomyosarcoma (RMS) mainly affects children, but also adolescents and (young) adults (AYA). ► As compared to children improvement in survival in AYA lags behind. ► AYA with RMS should...
|
J. Carlijn Van Gaal,
Eveline S.J.M. De Bont,
Suzanne E.J. Kaal,
Yvonne Versleijen-Jonkers,
Winette T.A. van der Graaf
et al.
|
Review article
(In Press Corrected Proof)
|
01 August 2011 |
|
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
DOI: 10.1016/j.critrevonc.2011.06.004
Abstract: Inconsistencies plague our understanding of the role of neutrophils in cancer and the literature provides evidence for a duality in neutrophil activity on the outcome of cancer. Here, the di...
|
H. Piccard,
R.J. Muschel,
G. Opdenakker
|
Review article
(In Press Corrected Proof)
|
28 July 2011 |
|
Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment
DOI: 10.1016/j.critrevonc.2011.06.003
Abstract: Discovery of the over-expression of Her-2/neu or the amplification of its regulatory gene in stomach and esophageal cancer has resulted in targeted treatment directed at this protein. The fa...
|
Judith Maresch,
Sebastian F. Schoppmann,
Christiane M.R. Thallinger,
Christoph C. Zielinski,
Michael Hejna
et al.
|
Review article
(In Press Corrected Proof)
|
25 July 2011 |
|
End-of-life care across Southern Europe: A critical review of cultural similarities and differences between Italy, Spain and Portugal
DOI: 10.1016/j.critrevonc.2011.06.002
Abstract: Evidence from a range of sources demonstrates that end-of-life (EoL) care practices and preferences vary across countries; culture is consistently one of the main explanations given for this...
|
Arantza Meñaca,
Natalie Evans,
Erin V.W. Andrew,
Franco Toscani,
Silvia Finetti,
Xavier Gómez-Batiste,
Irene J. Higginson,
Richard Harding,
Robert Pool,
Marjolein Gysels
et al.
|
Review article
(In Press Corrected Proof)
|
11 July 2011 |
|
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review
DOI: 10.1016/j.critrevonc.2011.06.001
Abstract: The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or seq...
|
Camillo Porta,
Cezary Szczylik,
Bernard Escudier
|
Review article
(In Press Corrected Proof)
|
06 July 2011 |
|
Primary plasma cell leukemia in the era of new drugs: Has something changed?
DOI: 10.1016/j.critrevonc.2011.04.005
Abstract: Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly im...
|
Pellegrino Musto,
Livio Pagano,
Maria Teresa Petrucci,
Fortunato Morabito,
Tommaso Caravita,
Francesco Di Raimondo,
Luca Baldini,
Patrizia Tosi,
Sara Bringhen,
Massimo Offidani,
Paola Omede’,
Antonino Neri,
Fiorella D’Auria,
Giovanni Battista Bochicchio,
Michele Cavo,
Mario Boccadoro,
Antonio Palumbo
et al.
|
Review article
(In Press Corrected Proof)
|
30 June 2011 |
|
Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer
DOI: 10.1016/j.critrevonc.2011.05.003
Abstract: Patients with non-small cell lung cancer (NSCLC) often present with advanced disease and cure rates are dismal with currently available treatment. Novel therapies including small molecule ty...
|
Antoinette Wozniak
|
Review article
(In Press Corrected Proof)
|
29 June 2011 |
|
Tailored imaging of islet cell tumors of the pancreas amidst increasing options
DOI: 10.1016/j.critrevonc.2011.05.006
Highlights: ► Pancreatic islet cell tumors are rare neuroendocrine tumors. ► They can be imaged using conventional and molecular imaging techniques. ► We organized the heterogeneous results described ...
|
Helle-Brit Fiebrich,
Sophie J. van Asselt,
Adrienne H. Brouwers,
Hendrik M. van Dullemen,
Milan E.J. Pijl,
Philip H. Elsinga,
Thera P. Links,
Elisabeth G.E. de Vries
et al.
|
Review article
(In Press Corrected Proof)
|
27 June 2011 |
|
Spinal analgesia for advanced cancer patients: An update
DOI: 10.1016/j.critrevonc.2011.05.007
Abstract: In the nineties, spinal analgesia has been described as an useful means to control pain in advanced cancer patients. The aim of this review was to update this information with a systematic a...
|
Sebastiano Mercadante,
Giampiero Porzio,
Vittorio Gebbia
|
Review article
(In Press Corrected Proof)
|
20 June 2011 |
|
Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates
DOI: 10.1016/j.critrevonc.2011.05.009
Highlights: ► The bone microenvironment facilitates distant metastasis from solid tumors. ► Disseminated tumor cells (DTCs) survive in bone marrow niches to seed later metastases. ► Using bisphosphona...
|
Rebecca Aft,
Jose-Ricardo Perez,
Noopur Raje,
Vera Hirsh,
Fred Saad
et al.
|
Review article
(In Press Corrected Proof)
|
20 June 2011 |
|
Circulating tumor cells in prostate cancer: A potential surrogate marker of survival
DOI: 10.1016/j.critrevonc.2011.05.004
Abstract: Prostate-specific antigen (PSA) levels in blood are widely used in prostate cancer (PCa) for the management of this disease at every stage of progression. Currently, PSA levels combined with...
|
Jérôme Doyen,
Catherine Alix-Panabières,
Paul Hofman,
Scott K. Parks,
Emmanuel Chamorey,
Hervé Naman,
Jean-Michel Hannoun-Lévi
et al.
|
Review article
(In Press Corrected Proof)
|
16 June 2011 |
|
Disseminated and circulating tumor cells in gastrointestinal oncology
DOI: 10.1016/j.critrevonc.2011.05.008
Abstract: Circulating (CTCs) and disseminated tumor cells (DTCs) are two different steps in the metastatic process. Several recent techniques have allowed detection of these cells in patients, and hav...
|
F.C. Bidard,
F.R. Ferrand,
F. Huguet,
P. Hammel,
C. Louvet,
D. Malka,
V. Boige,
M. Ducreux,
T. Andre,
A. de Gramont,
P. Mariani,
J.Y. Pierga
et al.
|
Review article
(In Press Corrected Proof)
|
16 June 2011 |
|
Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence
DOI: 10.1016/j.critrevonc.2011.05.005
Abstract: With increased understanding of cancer biology, a multitude of pathological, genetic, and molecular events that drive hepatocarcinogenesis, including angiogenesis, invasion, and metastasis, ...
|
Ashish Singhal,
Muralidharan Jayaraman,
Danny N. Dhanasekaran,
Vivek Kohli
|
Review article
(In Press Corrected Proof)
|
16 June 2011 |
|
Mantle cell lymphoma
DOI: 10.1016/j.critrevonc.2011.05.001
Abstract: MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to c...
|
Sergio Cortelazzo,
Maurilio Ponzoni,
Andrés J.M. Ferreri,
Martin Dreyling
|
Review article
(In Press Corrected Proof)
|
10 June 2011 |
|
Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches
DOI: 10.1016/j.critrevonc.2011.05.002
Abstract: In cancer, genetic and epigenetic alterations ultimately culminate in discordant activation of signal transduction pathways driving the malignant process. Pharmacological or biological inhib...
|
Arend H. Sikkema,
Wilfred F.A. den Dunnen,
Sander H. Diks,
Maikel P. Peppelenbosch,
Eveline S.J.M. de Bont
et al.
|
Review article
(In Press Corrected Proof)
|
06 June 2011 |
|
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
DOI: 10.1016/j.critrevonc.2011.04.009
Abstract: Metronomic (low-dose, long-term and frequently administered) chemotherapy has attracted renewed interest for the past few years, in particular because of possible positive association with m...
|
Nicolas Penel,
Antoine Adenis,
Guido Bocci
|
Review article
(In Press Corrected Proof)
|
06 June 2011 |
